New York, NY, and Tel Aviv, ISRAEL – April 21, 2022 - Todos Medical, Ltd. (OTCQB:TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the appointment of Philippe Goix as Chief Commercial Officer for Todos Medical's wholly-owned CLIA/CAP certified lab, Provista Diagnostics. Dr. Goix brings more than 25 years of experience in the Life Sciences tools, Diagnostics and Health Information areas to Provista.

Dr. Goix served as President & CEO of Prism Health Diagnostics, Inc. (PHDX), which he co-founded in late 2015 to establish ongoing wellness monitoring services as a business by delivering biomarker data to primary-care, functional medicine physicians and consumers to empower consumers to make better health decisions and offer personalized solutions. Prior to PHDX, Dr. Goix consulted for several healthcare companies from 2013 to 2015. Between 2004 through 2013, Dr. Goix served as President & CEO of Singulex, Inc., a personalized healthcare diagnostics company focused on improving outcomes in the $300 billion diabetes-cardiovascular industry.

While at Singulex, Singulex grew annual revenues from $0 and 10 employees, to annual revenues of over $60 million and more than 250 employees. During his tenure, Dr. Goix built a business comprising of three divisions: a laboratory testing division under CLIA, a proprietary Life Science Tools and pharma services division developing high sensitivity biomarker monitoring content, which was acquired by Merck Milipore in 2014 and an FDA-focused diagnostic development division. From 1997 to 2004, Dr. Goix served as President & CEO of Guava Technologies, Inc. where Dr. Goix successfully commercialized multiple commercial products still in use today. Guava Technologies was acquired by Merck Millipore in 2008.

With the appointment of Mr. Goix, Todos Medical strengthens its management team in preparing for growth and expansion beyond COVID. Recently, Todos reached a new daily COVID testing high of approximately 6,000 in a day. The lab also validated the Lumira Test which could potentially triple COVID-19 testing capacity. Todos believes it is well positioned to not only use the competitive advantage of having Covid capacity to obtain new patients during outbreaks, but to then maintain regular treatment afterwards. Todos does not intend to increase  its capacity but is increasing its assay  offering Infectious disease content and expanding to UTI, Wound and STD offering, in preparation for the launch of its high sensitivity blood breast cancer test, Videssa, which will be the core of its women health precision dx and personalized solution business.

“The precision testing and personalized solutions opportunities with Todos are boundless, I am very excited about it” said Phillippe Goix, Todos Chief Commercial Officer. “Right now our lab is focused on the COVID-19 resurgence and achieving operating efficiencies to capitalize on any surge. Beyond the financial windfall of the testing business, this influx of testing demand will also serve to help us refine our operations by exposing inefficiencies at much a quicker rate and allow us to battle test solutions as well. After COVID-19 we will turn our sights to the power of our proprietary Videssa Breast Cancer test. This test is vital to so many women that we would not be surprised to see testing soar once it is released. The lab will be prepared for this and should have no problem transitioning. Todos has state of the art cloud-based Laboratory Information Systems and equipment and automated testing processes which gives us a competitive advantage in integrating patient information and delivering results with a fast turn-around time for existing and new clients. The existing pipeline of new customers is firming, and we hope to announce some new contract wins during the next surge.”

“We have a real opportunity to win some business,” said Gerald Commissiong CEO of Todos Medical. “We built COVID-19 testing capacity as others have downsized and returned to ordinary business. Looking at the case data it looks like the testing business is well positioned to benefit from the next surge in cases. Philippe and his team are at the right spot at the right time. If we execute on our business plan we are going to attract customers that first use our labs for COVID-19 testing thereby opening the door for their long term business. We are confident that under Philippe’s leadership we can scale our COVID-19 testing strategy.”  

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB:TOMDF) engineers’ life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test. 

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting 

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from the competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.